GENERAL BIOL

About GENERAL BIOL

General Biol, officially known as General Biological Systems (Anhui) Co., Ltd., was established in 2014 and is headquartered in Chuzhou, Anhui, China. The company, led by Chairman and General Manager Yong Jingui, operates as a high-tech bio-company providing comprehensive solutions, raw materials, and services to the life sciences sector globally. Since its inception, General Biol has focused on the research, development, and application of synthetic biology. By 2022, the firm had successfully integrated six technology platforms covering gene synthesis, industrial primers, protein and antibody engineering, inspection and detection, and target engineering. This integration allows for a unified "gene + protein + antibody" business model.

The company's business model is centered on providing a one-stop shop for life science research services, core raw materials for diagnostic reagents, and early-stage R&D services for new drugs. Its client base includes major in-vitro diagnostic (IVD) and pharmaceutical companies in China, as well as clients in over 20 countries. General Biol serves the biomedical sector by supporting basic life science research, preclinical biopharmaceutical discovery, and the development of vaccines, nucleic acid drugs, and gene therapies. A significant milestone was achieved in December 2021, when the company established operations for small nucleic acid CMC (Chemistry, Manufacturing, and Controls) and CDMO (Contract Development and Manufacturing Organization) and began construction of an Oligo FlexFactory in collaboration with Cytiva.

General Biol has established a robust R&D framework, holding numerous patents and having developed several national standards. The company's growth has been supported by significant funding, including a Pre-IPO round of over 100 million yuan in June 2022, led by Huatai Investment. This financial backing is aimed at strengthening its synthetic biology platform and expanding its nucleic acid CDMO business. The company addresses the critical need for domestic production of upstream raw materials in China's biopharmaceutical industry. It provides a wide array of products, including industrial DNA primers, RNA synthesis, and core materials for both molecular and immune diagnostics, positioning itself as a key supplier for IVD companies.